The stock of Equillium Inc (EQ) has gone up by 12.44% for the week, with a -6.79% drop in the past month and a -21.50% drop in the past quarter. The volatility ratio for the week is 8.32%, and the volatility levels for the past 30 days are 10.61% for EQ. The simple moving average for the past 20 days is 6.14% for EQ’s stock, with a -45.93% simple moving average for the past 200 days.
Is It Worth Investing in Equillium Inc (NASDAQ: EQ) Right Now?
Company’s 36-month beta value is 1.13.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for EQ is 17.58M, and currently, short sellers hold a 11.90% ratio of that floaft. The average trading volume of EQ on July 09, 2025 was 650.13K shares.
EQ) stock’s latest price update
The stock price of Equillium Inc (NASDAQ: EQ) has surged by 13.53% when compared to previous closing price of $0.31, but the company has seen a 12.44% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-05-01 that LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor (AhR) modulator (EQ504), which was acquired through the acquisition of Ariagen, a biotechnology company that was majority owned by Equillium’s largest investor, Decheng Capital. AhR.
Analysts’ Opinion of EQ
Many brokerage firms have already submitted their reports for EQ stocks, with Leerink Partners repeating the rating for EQ by listing it as a “Market Perform.” The predicted price for EQ in the upcoming period, according to Leerink Partners is $1 based on the research report published on March 28, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see EQ reach a price target of $12. The rating they have provided for EQ stocks is “Buy” according to the report published on October 29th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to EQ, setting the target price at $14 in the report published on September 15th of the previous year.
EQ Trading at -3.51% from the 50-Day Moving Average
After a stumble in the market that brought EQ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.39% of loss for the given period.
Stock Fundamentals for EQ
Current profitability levels for the company are sitting at:
- -0.47 for the present operating margin
- 1.0 for the gross margin
The net margin for Equillium Inc stands at -0.46. The total capital return value is set at -1.34. Equity return is now at value -88.32, with -46.37 for asset returns.
Based on Equillium Inc (EQ), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -62.36.
Currently, EBITDA for the company is -7.57 million with net debt to EBITDA at 1.04. When we switch over and look at the enterprise to sales, we see a ratio of -0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.70.
Conclusion
In a nutshell, Equillium Inc (EQ) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
